Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Peng Liu(Jiangxi University of Traditional Chinese Medicine), Chuan Jin(Guangzhou Medical University), Hui Zhou(Hunan Cancer Hospital), Jianmin Yang(Canadian Food Inspection Agency), Jianda Hu(Fujian Medical University), Xiuhua Sun(Dalian Medical University), Hang Su(307th Hospital of Chinese People’s Liberation Army), Shan Zeng(Central South University), Yongping Song(First Affiliated Hospital of Zhengzhou University), Wei Li(Jilin University), Yan Xiong(University of Science and Technology Liaoning), Wei Zhang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qingyuan Zhang(Third Affiliated Hospital of Harbin Medical University), Wenqi Jiang(Sun Yat-sen University Cancer Center), Wenbin Qian(Ministry of Education of the People's Republic of China), Ming Hou(Qilu Hospital of Shandong University), Yuhuan Gao(Hebei Medical University), Zhengming Jin(Soochow University), Liqun Zou(Sichuan University), Lugui Qiu(Institute of Hematology & Blood Diseases Hospital), Jianfeng Zhou(Tongji Hospital)
Cited by 248
Related Papers
Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study
|Chinese Medical Journal|2020|1.4k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
|The Lancet Oncology|2016|1.2k
Targeting CD47 for cancer immunotherapy
|Journal of Hematology & Oncology|2021|342
Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
|Journal of Hematology & Oncology|2017|256
Genomic and Transcriptomic Characterization of Natural Killer T Cell Lymphoma
|Cancer Cell|2020|234